Harvoni and rival hep C drugs look set for approval in England – but NHS England may have the last word on controlling costs, finds Andrew McConaghie. Patients in England with hepatitis C (HCV) will ...

Merck & Co has axed two hepatitis drugs in its pipeline, a further indication that competitors think the market has peaked. The company already markets Zepatier (elbasvir+grazoprevir), which got off ...

U.S. President Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices are ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus ...

Read the latest healthcare, biotech, and pharmaceutical stock news and analysis. Uncover the latest research and company analysis to empower your investments.

Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...